press release
Focus development strategy on amyotrophic surface sclerosis with the macinib platform and on the second microtubule platform and search for a partnership for non-rare indications for macinib diseases
Launching the capital increase in the context of a private placement for a maximum amount of approximately €15.0 million.
Paris, April 21, 2023, at 10 p.m
AB Science SA (“the Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the implementation of a new strategy and the launch, in support of this new strategy, of raising capital by issuing new ordinary shares to each of which will be attached to share warrants with cancellation Preferential subscription rights for shareholders, by way of private placement up to a maximum of approximately €15 million (“capital increase”).
I. Focusing the development strategy on amyotrophic surface sclerosis with the macinib platform, on the second microtubule platform and seeking partnership for non-rare indications for macinib diseases
AB Science has decided to focus its development strategy as follows:
